Equity Overview
Price & Market Data
Price: $3.25
Daily Change: -$0.35 / 10.77%
Daily Range: $3.25 - $3.25
Market Cap: $292,989,376
Daily Volume: 3,000
Performance Metrics
1 Week: -9.72%
1 Month: -9.72%
3 Months: -3.27%
6 Months: -0.91%
1 Year: 8.33%
YTD: -9.72%
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country:
Details
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system) disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.